Major pharmaceutical companies are strategically capitalizing on these favorable regulatory environments. Firms such as Pfizer and AstraZeneca are channeling billions into oncology R&D, focusing on acquiring smaller biotech firms with innovative platforms, particularly in the fields of **Immunotherapy** and **Antibody-Drug Conjugates (ADCs)**. This investment surge is reflected in the...